iRhythm Technologies to Report Second Quarter 2020 Financial Results on August 6, 2020
iRhythm Technologies (NASDAQ: IRTC) has announced it will release its Q2 2020 financial results after market close on August 6, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
iRhythm Technologies (NASDAQ: IRTC) has announced it will release its Q2 2020 financial results after market close on August 6, 2020. The management team will conduct a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Investors can access the call via a live and archived webcast on the company’s website.
iRhythm is recognized for its innovative approach to cardiac care, utilizing wearable biosensors and cloud-based analytics to enhance arrhythmia detection.
Details
News Market Reaction – IRTC
The recorded move for IRTC in the trading session of this news was +0.82%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, July 21, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced that it will release financial results for the second quarter 2020 after the close of trading on Thursday, August 6, 2020. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Investors interested in listening to the conference call may do so by accessing the live and archived webcast of the event available on the “Investors” section of the company’s website at: www.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
investors@irhythmtech.com
Media Contact
Saige Smith
(262) 289-7065
irhythm@highwirepr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.